Summary

Biopharmaceutical Fermentation Systems Market – Scope of Report
TMR’s report on the global biopharmaceutical fermentation systems market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global biopharmaceutical fermentation systems market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global biopharmaceutical fermentation systems market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the biopharmaceutical fermentation systems market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global biopharmaceutical fermentation systems market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global biopharmaceutical fermentation systems market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global biopharmaceutical fermentation systems market.

The report delves into the competitive landscape of the global biopharmaceutical fermentation systems market. Key players operating in the global biopharmaceutical fermentation systems market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global biopharmaceutical fermentation systems market profiled in this report.

Key Questions Answered in Global biopharmaceutical fermentation systems Market Report
• What is the sales/revenue generated by biopharmaceutical fermentation systems across all regions during the forecast period?
• What are the opportunities in the global biopharmaceutical fermentation systems market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Biopharmaceutical Fermentation Systems Market – Research Objectives and Research Approach
The comprehensive report on the global biopharmaceutical fermentation systems market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global biopharmaceutical fermentation systems market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global biopharmaceutical fermentation systems market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Biopharmaceutical Fermentation Systems Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Biopharmaceutical Fermentation Systems Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Biopharmaceutical Fermentation Systems Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Upstream Products
6.3.1.1. Fermenters
6.3.1.2. Bioprocess Analyzers
6.3.1.3. Process Monitoring Devices
6.3.1.4. Culture & Media Preparation
6.3.1.5. Culture Media and Buffers & Inducers
6.3.1.6. Other Upstream Products
6.3.2. Downstream Products
6.3.2.1. Filtration & Separation Systems
6.3.2.2. Chromatography
6.3.2.3. Consumables & Accessories
6.3.2.4. Other Downstream Products
6.4. Market Attractiveness Analysis, by Product
7. Global Biopharmaceutical Fermentation Systems Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Recombinant Proteins
7.3.2. Monoclonal Antibodies
7.3.3. Antibiotics
7.3.4. Probiotics
7.3.5. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Biopharmaceutical Fermentation Systems Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Biopharmaceutical Companies
8.3.2. Contract Manufacturing Organizations
8.3.3. Contract Research Organizations
8.3.4. Academic Research Institutes
8.3.5. Food Industry
8.3.6. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Biopharmaceutical Fermentation Systems Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Biopharmaceutical Fermentation Systems Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product, 2017–2031
10.3.1. Upstream Products
10.3.1.1. Fermenters
10.3.1.2. Bioprocess Analyzers
10.3.1.3. Process Monitoring Devices
10.3.1.4. Culture & Media Preparation
10.3.1.5. Culture Media and Buffers & Inducers
10.3.1.6. Other Upstream Products
10.3.2. Downstream Products
10.3.2.1. Filtration & Separation Systems
10.3.2.2. Chromatography
10.3.2.3. Consumables & Accessories
10.3.2.4. Other Downstream Products
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Recombinant Proteins
10.4.2. Monoclonal Antibodies
10.4.3. Antibiotics
10.4.4. Probiotics
10.4.5. Others
10.5. Market Value Forecast, by End-user, 2017–2031
10.5.1. Biopharmaceutical Companies
10.5.2. Contract Manufacturing Organizations
10.5.3. Contract Research Organizations
10.5.4. Academic Research Institutes
10.5.5. Food Industry
10.5.6. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Product
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Biopharmaceutical Fermentation Systems Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product, 2017–2031
11.3.1. Upstream Products
11.3.1.1. Fermenters
11.3.1.2. Bioprocess Analyzers
11.3.1.3. Process Monitoring Devices
11.3.1.4. Culture & Media Preparation
11.3.1.5. Culture Media and Buffers & Inducers
11.3.1.6. Other Upstream Products
11.3.2. Downstream Products
11.3.2.1. Filtration & Separation Systems
11.3.2.2. Chromatography
11.3.2.3. Consumables & Accessories
11.3.2.4. Other Downstream Products
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Recombinant Proteins
11.4.2. Monoclonal Antibodies
11.4.3. Antibiotics
11.4.4. Probiotics
11.4.5. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Biopharmaceutical Companies
11.5.2. Contract Manufacturing Organizations
11.5.3. Contract Research Organizations
11.5.4. Academic Research Institutes
11.5.5. Food Industry
11.5.6. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Biopharmaceutical Fermentation Systems Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product, 2017–2031
12.3.1. Upstream Products
12.3.1.1. Fermenters
12.3.1.2. Bioprocess Analyzers
12.3.1.3. Process Monitoring Devices
12.3.1.4. Culture & Media Preparation
12.3.1.5. Culture Media and Buffers & Inducers
12.3.1.6. Other Upstream Products
12.3.2. Downstream Products
12.3.2.1. Filtration & Separation Systems
12.3.2.2. Chromatography
12.3.2.3. Consumables & Accessories
12.3.2.4. Other Downstream Products
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Recombinant Proteins
12.4.2. Monoclonal Antibodies
12.4.3. Antibiotics
12.4.4. Probiotics
12.4.5. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Biopharmaceutical Companies
12.5.2. Contract Manufacturing Organizations
12.5.3. Contract Research Organizations
12.5.4. Academic Research Institutes
12.5.5. Food Industry
12.5.6. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Biopharmaceutical Fermentation Systems Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product, 2017–2031
13.3.1. Upstream Products
13.3.1.1. Fermenters
13.3.1.2. Bioprocess Analyzers
13.3.1.3. Process Monitoring Devices
13.3.1.4. Culture & Media Preparation
13.3.1.5. Culture Media and Buffers & Inducers
13.3.1.6. Other Upstream Products
13.3.2. Downstream Products
13.3.2.1. Filtration & Separation Systems
13.3.2.2. Chromatography
13.3.2.3. Consumables & Accessories
13.3.2.4. Other Downstream Products
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Recombinant Proteins
13.4.2. Monoclonal Antibodies
13.4.3. Antibiotics
13.4.4. Probiotics
13.4.5. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Biopharmaceutical Companies
13.5.2. Contract Manufacturing Organizations
13.5.3. Contract Research Organizations
13.5.4. Academic Research Institutes
13.5.5. Food Industry
13.5.6. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Biopharmaceutical Fermentation Systems Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Product, 2017–2031
14.3.1. Upstream Products
14.3.1.1. Fermenters
14.3.1.2. Bioprocess Analyzers
14.3.1.3. Process Monitoring Devices
14.3.1.4. Culture & Media Preparation
14.3.1.5. Culture Media and Buffers & Inducers
14.3.1.6. Other Upstream Products
14.3.2. Downstream Products
14.3.2.1. Filtration & Separation Systems
14.3.2.2. Chromatography
14.3.2.3. Consumables & Accessories
14.3.2.4. Other Downstream Products
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Recombinant Proteins
14.4.2. Monoclonal Antibodies
14.4.3. Antibiotics
14.4.4. Probiotics
14.4.5. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Biopharmaceutical Companies
14.5.2. Contract Manufacturing Organizations
14.5.3. Contract Research Organizations
14.5.4. Academic Research Institutes
14.5.5. Food Industry
14.5.6. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. GE Healthcare
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Thermo Fisher Scientific Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Danaher Corporation
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Sartorius Stedim Biotech
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. F. Hoffman-La Roche Ltd.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Eppendorf AG
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Merck KGaA
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Nova Biomedical
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Lonza Group AG
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. BD
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview